Trial Profile
A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0077 as a Single Agent in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination With Endocrine and Targeted Therapies in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Inavolisib (Primary) ; Fulvestrant; Letrozole; Metformin; Palbociclib; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer; HER2 negative breast cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Genentech; Roche
- 12 Dec 2022 Planned End Date changed from 1 Dec 2022 to 30 Nov 2024.
- 12 Dec 2022 Planned primary completion date changed from 30 Nov 2022 to 30 Nov 2024.
- 07 Jun 2022 Results (at data cutoff: 07/26/21; n=57) assessing long-term tolerability were presented at the 58th Annual Meeting of the American Society of Clinical Oncology.